HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CAY 10471

a prostaglandin D2 receptor antagonist; structure in first source

Also Known As:

CAY-10471; CAY10471

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Carbazoles: 32
        CAY 10471: 2
  - 3-Ring Heterocyclic Compounds
    - Carbazoles: 32
      - CAY 10471: 2
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - CAY 10471: 2
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - CAY 10471: 2

Experts

1.	Agoni, Clement: 1 article (01/2019)
2.	Issahaku, Abdul R: 1 article (01/2019)
3.	Kubi, Patrick A: 1 article (01/2019)
4.	Kumi, Ransford O: 1 article (01/2019)
5.	Olotu, Fisayo A: 1 article (01/2019)
6.	Soliman, Mahmoud E S: 1 article (01/2019)
7.	Soremekun, Opeyemi S: 1 article (01/2019)

Related Diseases

1.	Allergic Rhinitis 01/01/2019 - "Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma."
2.	Obesity 01/01/2023 - "Treatment with CAY10471 enhanced NFATc1 activity in the skeletal muscles and ameliorated HFD-induced obesity (P < 0.05 vs. saline) and insulin resistance in mice. "
3.	Muscular Dystrophies (Muscular Dystrophy) 01/01/2023 - "X-linked muscular dystrophy (MDX) mice and HFD-challenged mice were treated with the selective DP2 inhibitor CAY10471. "
4.	Insulin Resistance 01/01/2023 - "Treatment with CAY10471 enhanced NFATc1 activity in the skeletal muscles and ameliorated HFD-induced obesity (P < 0.05 vs. saline) and insulin resistance in mice. "
5.	Asthma (Bronchial Asthma) 01/01/2019 - "Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma."

Related Drugs and Biologics

1.	fevipiprant